BACKGROUND: The outcome of treatment for pediatric Hodgkin lymphoma (HL) is excellent using chemotherapy and radiation. However, a minority of patients will relapse after treatment, but additional therapy achieves durable second remission in many cases. The optimal surveillance strategy after modern therapy for HL has not been well defined. PROCEDURES: We reviewed the outcomes of pediatric patients with HL treated between 1990 and 2006 to determine the primary event that led to the detection of relapse. We determined the probability of relapse detection by routine follow-up procedures, including history, physical examination, laboratory tests, and imaging, and determined the impact of each of these screening methods on the likelihood of survival after relapse. RESULTS: Relapse occurred in 64 of 402 evaluable patients (15.9%) at a median of 1.7 years from the time of diagnosis. The majority of relapses (60%) were diagnosed at a routine visit, and patient complaint was the most common initial finding that led to a diagnosis of relapse (47% of relapses). An abnormal finding on physical examination was the primary event in another 17% of relapses, and imaging abnormalities led to the diagnosis in the remaining 36%. Laboratory abnormalities were never the primary finding. The method of detection of relapse and timing (whether detected at a routine visit or an extra visit) did not impact survival. CONCLUSIONS: In pediatric HL, most relapses are identified through history and physical examination. Frequent imaging of asymptomatic patients does not appear to impact survival and is probably not warranted.
BACKGROUND: The outcome of treatment for pediatric Hodgkin lymphoma (HL) is excellent using chemotherapy and radiation. However, a minority of patients will relapse after treatment, but additional therapy achieves durable second remission in many cases. The optimal surveillance strategy after modern therapy for HL has not been well defined. PROCEDURES: We reviewed the outcomes of pediatricpatients with HL treated between 1990 and 2006 to determine the primary event that led to the detection of relapse. We determined the probability of relapse detection by routine follow-up procedures, including history, physical examination, laboratory tests, and imaging, and determined the impact of each of these screening methods on the likelihood of survival after relapse. RESULTS: Relapse occurred in 64 of 402 evaluable patients (15.9%) at a median of 1.7 years from the time of diagnosis. The majority of relapses (60%) were diagnosed at a routine visit, and patient complaint was the most common initial finding that led to a diagnosis of relapse (47% of relapses). An abnormal finding on physical examination was the primary event in another 17% of relapses, and imaging abnormalities led to the diagnosis in the remaining 36%. Laboratory abnormalities were never the primary finding. The method of detection of relapse and timing (whether detected at a routine visit or an extra visit) did not impact survival. CONCLUSIONS: In pediatric HL, most relapses are identified through history and physical examination. Frequent imaging of asymptomatic patients does not appear to impact survival and is probably not warranted.
Authors: Stephan D Voss; Lu Chen; Louis S Constine; Allen Chauvenet; Thomas J Fitzgerald; Sue C Kaste; Thomas Slovis; Cindy L Schwartz Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544
Authors: Melissa M Rhodes; Dominique Delbeke; James A Whitlock; William Martin; John F Kuttesch; Haydar A Frangoul; Sadhna Shankar Journal: J Pediatr Hematol Oncol Date: 2006-05 Impact factor: 1.289
Authors: Sarah S Donaldson; Melissa M Hudson; Kathleen R Lamborn; Michael P Link; Larry Kun; Amy Louise Billett; Karen C Marcus; Craig A Hurwitz; Jeffrey A Young; Nancy J Tarbell; Howard J Weinstein Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: Melissa M Hudson; Matthew Krasin; Michael P Link; Sarah S Donaldson; Catherine Billups; Thomas E Merchant; Larry Kun; Amy L Billet; Sue Kaste; Nancy J Tarbell; Scott Howard; Alison M Friedmann; Craig A Hurwitz; Jeffrey A Young; Karen C Marcus; Shesh Rai; Traci Cowan; Howard J Weinstein Journal: J Clin Oncol Date: 2004-11-15 Impact factor: 44.544
Authors: Justine M Kahn; Kara M Kelly; Qinglin Pei; Rizvan Bush; Debra L Friedman; Frank G Keller; Smita Bhatia; Tara O Henderson; Cindy L Schwartz; Sharon M Castellino Journal: J Clin Oncol Date: 2019-09-20 Impact factor: 44.544